Search Results - "Virone, A"

Refine Results
  1. 1

    Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome by Nocturne, G., Virone, A., Ng, Wan‐Fai, Le Guern, V., Hachulla, E., Cornec, D., Daien, C., Vittecoq, O., Bienvenu, B., Marcelli, C., Wendling, D., Amoura, Z., Dhote, R., Lavigne, C., Fior, R., Gottenberg, J. E., Seror, R., Mariette, X.

    Published in Arthritis & rheumatology (Hoboken, N.J.) (01-04-2016)
    “…Objective To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS). Methods A multicenter case–control survey…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells by Delarue, Françoise, Virone, Angela, Hagege, Jacqueline, Lacave, Roger, Peraldi, Marie-Nëlle, Adida, Colette, Rondeau, Eric, Feunteun, Jean, Sraer, Jean-Daniel

    Published in Kidney international (01-11-1991)
    “…Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. Human subcultures (third passage) of glomerular visceral epithelial cells…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    In vitro and in vivo effects of UP 269‐6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation by Virone‐Oddos, A., Desangle, V., Provost, D., Cazes, M., Caussade, F., Cloarec, A.

    Published in British journal of pharmacology (01-02-1997)
    “…1 The present studies were designed to measure the affinity of UP 269‐6, a newly developed angiotensin AT1 receptor antagonist, for vascular AT1 receptors from…”
    Get full text
    Journal Article
  7. 7

    In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist by Caussade, F, Virone-Oddos, A, Delchambre, C, Cazes, M, Versigny, A, Cloarec, A

    Published in Fundamental & clinical pharmacology (01-01-1995)
    “…f1p4in vitro pharmacology of UP 269-6, a novel nonpeptide angiotensin II antagonist, was examined in radioligand binding and functional isolated tissue assays…”
    Get more information
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Synthesis and angiotensin II receptor antagonist activity of C-linked pyrimidine derivatives by Nicolaï, E, Curé, G, Goyard, J, Kirchner, M, Teulon, JM, Versigny, A, Cazes, M, Virone-Oddos, A, Caussade, F, Cloarec, A

    “…The synthesis and pharmacological activity of nonpeptide angiotensin II (Ang II) receptor antagonists are presented. These 3- N-substituted pyrimidine-4(3…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists by Nicolai, Eric, Goyard, Joel, Benchetrit, Thierry, Teulon, Jean Marie, Caussade, Francois, Virone, Angela, Delchambre, Chantal, Cloarec, Alix

    Published in Journal of medicinal chemistry (01-04-1993)
    “…A series of 1-benzylbenzimidazole and 3-benzylimidazo[4,5-b]pyridine substituted in the 2-position by an alkanoic or mercaptoalkanoic acid chain was…”
    Get full text
    Journal Article
  17. 17

    Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression by COCHET, O, KENIGSBERG, M, DELUMEAU, I, VIRONE-ODDOS, A, MULTON, M.-C, FRIDMAN, W. H, SCHWEIGHOFFER, F, TEILLAUD, J.-L, TOCQUE, B

    Published in Cancer research (Chicago, Ill.) (15-03-1998)
    “…Mutated ras genes are found in a large number of human tumors and, therefore, constitute one of the primary targets for cancer treatment. Microinjection of the…”
    Get full text
    Journal Article
  18. 18

    Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes by Virone, A, Monier, R, Zerial, A, Lavelle, F, Feunteun, J

    Published in International journal of cancer (09-07-1992)
    “…Four murine cellular tumor models expressing various combinations of oncogenes (SV40 large T and v-Ha-ras, SV40 large T and v-src, SV40 large T and neu,…”
    Get more information
    Journal Article
  19. 19
  20. 20

    Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2 by Bougeret, C, Virone-Oddos, A, Adeline, E, Lacroix, F, Lefranc, C, Ferrero, L, Huet, T

    Published in Cancer gene therapy (01-05-2000)
    “…Recently, a new p53 derivative has been designed, namely chimeric tumor suppressor 1 (CTS1), in which the p53 domains that are known to mediate p53…”
    Get full text
    Journal Article